• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.

作者信息

Kim Hyun Kuk, Kubica Jacek, Jeong Young-Hoon

机构信息

Department of Internal Medicine, Chosun University College of Medicine, Gwangju, South Korea.

Department of Cardiology and Internal Medicine, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland.

出版信息

JAMA. 2021 Mar 2;325(9):890. doi: 10.1001/jama.2020.26020.

DOI:10.1001/jama.2020.26020
PMID:33651086
Abstract
摘要

相似文献

1
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
JAMA. 2021 Mar 2;325(9):890. doi: 10.1001/jama.2020.26020.
2
Effect of ticagrelor and clopidogrel on platelet aggregation function after percutaneous coronary intervention in patients with acute coronary syndrome.替格瑞洛和氯吡格雷对急性冠状动脉综合征患者经皮冠状动脉介入治疗后血小板聚集功能的影响。
J Biol Regul Homeost Agents. 2019;33(2):439-445.
3
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.替格瑞洛与氯吡格雷对行经皮冠状动脉介入治疗的急性冠状动脉综合征患者主要不良冠状动脉事件的影响。
JAMA Intern Med. 2020 Mar 1;180(3):420-428. doi: 10.1001/jamainternmed.2019.6447.
4
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.替格瑞洛与氯吡格雷用于接受经皮介入治疗的急性冠脉综合征患者——回复
JAMA. 2021 Mar 2;325(9):890-891. doi: 10.1001/jama.2020.26023.
5
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.在经皮冠状动脉介入治疗后急性冠脉综合征患者的早期和晚期转换为氯吡格雷的疗效和安全性。
Platelets. 2020;31(3):337-343. doi: 10.1080/09537104.2019.1609668. Epub 2019 May 1.
6
Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome.强效P2Y12抑制剂与氯吡格雷在老年急性冠脉综合征患者中的疗效与安全性比较
Chin Med J (Engl). 2020 Nov 5;133(21):2628-2629. doi: 10.1097/CM9.0000000000001119.
7
Comparison of Antiplatelet Effects and Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Chinese Patients With Acute Coronary Syndrome.替格瑞洛与氯吡格雷在中国急性冠脉综合征患者中抗血小板作用及临床结局的比较
Am J Ther. 2022;29(5):e606-e608. doi: 10.1097/MJT.0000000000001190. Epub 2020 May 12.
8
Risk of ticagrelor versus clopidogrel discontinuation.
Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):356. doi: 10.1016/j.rec.2023.11.018. Epub 2024 Jan 16.
9
Risk of ticagrelor versus clopidogrel discontinuation. Response.
Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):356-357. doi: 10.1016/j.rec.2023.11.015. Epub 2024 Jan 12.
10
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.60毫克剂量替格瑞洛对中国慢性冠状动脉综合征患者的血小板抑制作用强于氯吡格雷：一项随机、单盲、交叉研究。
Thromb Res. 2020 Jun;190:60-61. doi: 10.1016/j.thromres.2020.03.014. Epub 2020 Mar 19.